This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

CNBC’s “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.